Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN® and Belinostat at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting

Promising ZEVALIN data reported in patients with diffuse large B-cell lymphoma (DLBCL); data suggest reduced need for standard chemotherapy. ZEVALIN poster presentations also show positive results in diverse patient populations, including those receiving stem cell transplants and the elderly Belinostat therapy shows encouraging activity in combination with chemotherapy regimen against aggressive form of lymphoma Spectrum Pharmaceuticals

today announced promising clinical data in five poster presentations for ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, as well as a poster presentation and one e-abstract publication for belinostat, at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois, from June 1-5, 2012. ZEVALIN – Promising clinical findings in DLBCL, including in elderly patients; ZEVALIN further associated with reduced need for chemotherapy